Press Releases
Greedy Drug Company Loses In Court, Notching Another Win For Seniors Benefiting From Medicare Negotiation
WASHINGTON, DC — Today, the US District Court for the District of Delaware released its decision in AstraZeneca Pharmaceuticals LP et al. v. Becerra et al., ruling against the pharmaceutical giant in its attempt to ban Medicare from negotiating lower drug prices with manufacturers under the Inflation Reduction Act. Accountable.US Executive Director Tony Carrk issued the following statement in response:
Big drug company executives are stopping at nothing to price gouge Americans and pad their profits. First they spent millions to stop the Inflation Reduction Act’s Medicare price negotiation authority and failed. Now they are trying to do it by clogging the judicial system with meritless lawsuits. Today’s ruling is a victory for the Biden administration’s historic cost-lowering program and for seniors who need lower prescription drug costs.”
The decision follows a ruling earlier this month in the US District Court for the Western District of Texas that tossed out a lawsuit against the Biden administration brought by the Pharmaceutical Research and Manufacturers of America (PhRMA) and its allies that also sought to block Medicare from negotiating lower drug prices.
More on Gross Pharma Profiteering From Accountable.US:
- Drug Company Giant Suing to End Biden Cost-Lowering Rx Program Boasts Nearly $6B in Annual Profits
- Watchdog: PhRMA Lawsuit Against Medicare Negotiation Tossed in Texas Was Desperate Act of Greed
- REPORT: PhRMA Gave Half a Million to Election Denying Fringe Right Groups
- Ahead of Senate Drug Pricing Hearing, Report Finds PhRMA CEOs Rewarded Selves & Investors While Hiking Patients’ Costs
